{"id":744922,"date":"2014-09-28T02:15:00","date_gmt":"2014-09-28T02:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/"},"modified":"2023-03-22T00:04:51","modified_gmt":"2023-03-22T04:04:51","slug":"merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/","title":{"rendered":"Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014"},"content":{"rendered":"<p class=\"bwalignc\">       KEYTRUDA<sup>\u00ae<\/sup> monotherapy achieved 31 percent overall        response rate in patients with PD-L1 positive, advanced gastric cancer     <\/p>\n<p class=\"bwalignc\">       Phase 2 study to be initiated in first quarter of 2015 (KEYNOTE-059)     <\/p>\n<\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the first presentation of data on the investigational<br \/>\n      use of KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) \u2013 the company\u2019s anti-PD-1<br \/>\n      therapy \u2013 in PD-L1 positive, advanced gastric cancer. The early findings<br \/>\n      presented showed an overall response rate (confirmed and unconfirmed) of<br \/>\n      31 percent with KEYTRUDA as monotherapy, as measured by investigator<br \/>\n      assessed, RECIST v1.1 (n= 12\/39: 95% CI, 17-47). Similar overall<br \/>\n      response rates were observed in Asian patients (a population with a high<br \/>\n      incidence of gastric cancer) and non-Asian patients. At the time of<br \/>\n      analysis, response durations ranged from 8+ to 20+ weeks with 11 of 12<br \/>\n      responders continuing on therapy.\n    <\/p>\n<p>\n      These data, from a cohort of the ongoing Phase 1b KEYNOTE-012 study,<br \/>\n      were presented today, as part of a late-breaking oral session, by Dr.<br \/>\n      Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan, at the European<br \/>\n      Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain<br \/>\n      (ABSTRACT #LBA15). Data investigating the use of KEYTRUDA monotherapy in<br \/>\n      five tumor types will be presented at ESMO 2014.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg every<br \/>\n      three weeks for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma and disease progression following ipilimumab and, if<br \/>\n      BRAF V600 mutation positive, a BRAF inhibitor. This indication is<br \/>\n      approved under accelerated approval based on tumor response rate and<br \/>\n      durability of response. An improvement in survival or disease-related<br \/>\n      symptoms has not yet been established. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      \u201cMerck is advancing the development of KEYTRUDA across different tumor<br \/>\n      types and lines of therapy,\u201d said Dr. Alise Reicin, vice president,<br \/>\n      oncology, Merck Research Laboratories. \u201cWe are encouraged by the signals<br \/>\n      of anti-tumor activity in advanced gastric cancer, and are eager to move<br \/>\n      ahead with the Phase 2 study to better understand the potential of<br \/>\n      KEYTRUDA in advanced gastric cancer.\u201d\n    <\/p>\n<p>\n      <b>Early findings for investigational use of KEYTRUDA in advanced<br \/>\n      gastric cancer<\/b>\n    <\/p>\n<p>\n      Data from a cohort of the ongoing Phase 1b KEYNOTE-012 study evaluated<br \/>\n      KEYTRUDA monotherapy at 10 mg\/kg every two weeks in patients with<br \/>\n      advanced gastric cancer whose tumors were determined to be positive for<br \/>\n      PD-L1 expression (n=39). As measured by Merck\u2019s proprietary<br \/>\n      immunohistochemistry (IHC) clinical trial assay, tumors were classified<br \/>\n      as PD-L1 positive based on greater than or equal to one percent of tumor<br \/>\n      cells demonstrating expression of the PD-L1 marker, or any positive<br \/>\n      staining with the same reagent in tumor stroma. Enrollment was designed<br \/>\n      to include an equal number of Asian and non-Asian patients. The majority<br \/>\n      of patients had received two or more prior lines of therapy.\n    <\/p>\n<p>\n      <b>Antitumor activity by Response Evaluation Criteria in Solid Tumors<br \/>\n      (RECIST) v1.1*<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>Total<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>n = 39<\/b>\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>Non-Asian<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>n = 20<\/b>\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n          <b>Asian<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>n = 19<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Overall Response Rate (ORR), % (95% CI)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          31 (17-47)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          30 (12-54)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          31 (12-56)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Disease Control Rate (DCR), % (95% CI)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          43 (28-60)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          35 (15-59)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          52 (29-75)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\" colspan=\"7\">\n          Best overall response, n (%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<ul>\n<li>\n              Complete response\n            <\/li>\n<\/ul>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<ul>\n<li>\n              Partial response\n            <\/li>\n<\/ul>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          12 (31)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          6 (30)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          6 (32)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<ul>\n<li>\n              Stable disease\n            <\/li>\n<\/ul>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          5 (13)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1 (5)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4 (21)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<ul>\n<li>\n              Progressive disease\n            <\/li>\n<\/ul>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          21 (54)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          12 (60)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          9 (47)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n<ul>\n<li>\n              No assessment\n            <\/li>\n<\/ul>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1 (2)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1 (5)\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      <b>*<\/b>Analysis cut-off date: August 6, 2014\n    <\/p>\n<p>\n      Using a prototype assay for PD-L1 assessment, there was evidence of a<br \/>\n      preliminary relationship between PD-L1 expression and ORR (P = 0.071)\n    <\/p>\n<p>\n      In the study, tumor shrinkage was demonstrated in 41 percent of<br \/>\n      evaluable patients who had measurable disease with one post baseline<br \/>\n      scan, per RECIST v1.1 criteria.\n    <\/p>\n<p>\n      Adverse events were consistent with previously reported safety data for<br \/>\n      KEYTRUDA. The most common investigator-assessed, treatment-related<br \/>\n      adverse events (occurring in greater than five percent) included<br \/>\n      hypothyroidism (12.8%) and fatigue (12.8%). Grade 3-5<br \/>\n      investigator-assessed, treatment-related adverse events occurred in a<br \/>\n      total of three patients, with one patient each in peripheral sensory<br \/>\n      neuropathy (Grade 3), hypoxia (Grade 5) and pneumonitis (Grade 4). No<br \/>\n      infusion-related reactions were observed and no patients discontinued<br \/>\n      KEYTRUDA due to a treatment-related adverse reaction. One<br \/>\n      treatment-related death due to hypoxia, as assessed by the investigator,<br \/>\n      was reported.\n    <\/p>\n<p>\n      <b>About the KEYNOTE-012 study<\/b>\n    <\/p>\n<p>\n      KEYNOTE-012 is an ongoing multi-center, non-randomized Phase 1b trial<br \/>\n      evaluating the safety, tolerability, and anti-tumor activity of KEYTRUDA<br \/>\n      monotherapy in patients with advanced triple negative breast cancer<br \/>\n      (TNBC), advanced head and neck cancer, advanced urothelial (bladder)<br \/>\n      cancer, or advanced gastric cancer. The primary endpoints of the study<br \/>\n      include overall safety, tolerability and anti-tumor activity (as<br \/>\n      measured by RECIST v1.1) in PD-L1 positive tumors; secondary endpoints<br \/>\n      include progression-free survival (PFS), overall survival (OS) and<br \/>\n      duration of response.\n    <\/p>\n<p>\n      <b>Presentation of additional findings investigating the use of KEYTRUDA<br \/>\n      in advanced non-small cell lung cancer (NSCLC)<\/b>\n    <\/p>\n<p>\n      Also presented today, were updated findings in patients with<br \/>\n      treatment-na\u00efve or previously treated advanced non-small cell lung<br \/>\n      cancer (NSCLC) across cohorts from the ongoing Phase 1b KEYNOTE-001<br \/>\n      study (Abstract #LBA43). Data presented in a late-breaking oral session<br \/>\n      showed anti-tumor activity [overall response rate (ORR)] with KEYTRUDA<br \/>\n      in both treatment-na\u00efve and previously treated patients with advanced<br \/>\n      NSCLC (n=236) of 26 and 20 percent, respectively, across all doses and<br \/>\n      schedules assessed as measured by independent central review, RECIST<br \/>\n      v1.1. Analysis by dose (2 mg\/kg every three weeks, 10 mg\/kg every three<br \/>\n      weeks, and 10 mg\/kg every two weeks) showed comparable ORR across dosing<br \/>\n      schedules (33 percent, 21 percent, and 21 percent, respectively).\n    <\/p>\n<p>\n      <b>About KEYTRUDA (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA<br \/>\n      (pembrolizumab). The most frequent serious adverse drug reactions<br \/>\n      reported in 2% or more of patients were renal failure, dyspnea,<br \/>\n      pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>About gastric cancer<\/b>\n    <\/p>\n<p>\n      Gastric cancer, also called stomach cancer, is a type of cancer that<br \/>\n      begins in the stomach.<sup>1<\/sup> Most gastric cancers are<br \/>\n      adenocarcinomas, which develop from the cells of the innermost lining<br \/>\n      (mucosa) of the stomach.<sup>1<\/sup> Among others, risk factors for<br \/>\n      gastric cancer include gender, age, ethnicity, geography and bacterial<br \/>\n      infection with <i>Helicobacter pylori<\/i>.<sup>1<\/sup> More than 70<br \/>\n      percent of gastric cancer cases occur in developing countries, with half<br \/>\n      of all cases occurring in Eastern Asia (predominately China).<sup>2<\/sup><br \/>\n      Worldwide, gastric cancer is the fifth most common type of cancer and<br \/>\n      the third leading cause of cancer death.<sup>2<\/sup>\n    <\/p>\n<p>\n      <b>Our focus on cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into biomedical<br \/>\n      innovations to help people with cancer worldwide. For Merck Oncology,<br \/>\n      helping people fight cancer is our passion, supporting accessibility to<br \/>\n      our cancer medicines is our commitment, and pursuing research in<br \/>\n      immuno-oncology is our focus to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=50951007&amp;newsitemid=20140928005065&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=3cf825f23300f87bad65d97546a1d6ab\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=50951007&amp;newsitemid=20140928005065&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=2a902aa7930b8aa7abf2abffc814610d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=50951007&amp;newsitemid=20140928005065&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=ce6c91dc42eb152b4ee26a836cdf6302\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=50951007&amp;newsitemid=20140928005065&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=6dcc97dedf0dc12f406a8948dd5cd53f\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=50951007&amp;newsitemid=20140928005065&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=473962adcc0bd12afbaf7dbcc7f45f31\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50951007&amp;newsitemid=20140928005065&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=2bed8884286b60d7616dd24b706db394\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=50951007&amp;newsitemid=20140928005065&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=7&amp;md5=0aff8243957f3ea6fbd3a20657bc599a\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=50951007&amp;newsitemid=20140928005065&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=8&amp;md5=7339ce62d3e55b4d2d5669e00f9ff378\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><sup><b>\u00ae <\/b><\/sup><b>is a registered trademark of Merck<br \/>\n      Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.<\/b>\n    <\/p>\n<p>\n      <sup>1<\/sup> American Cancer Society. Stomach Cancer. <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cancer.org%2Facs%2Fgroups%2Fcid%2Fdocuments%2Fwebcontent%2F003141-pdf.pdf&amp;esheet=50951007&amp;newsitemid=20140928005065&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.cancer.org%2Facs%2Fgroups%2Fcid%2Fdocuments%2Fwebcontent%2F003141-pdf.pdf&amp;index=9&amp;md5=0eba495f1f620747efb8e3568a09c6a9\" rel=\"nofollow\">http:\/\/www.cancer.org\/acs\/groups\/cid\/documents\/webcontent\/003141-pdf.pdf<\/a>.<br \/>\n      Accesses September 17, 2014.\n    <\/p>\n<p>\n      <sup>2<\/sup> World Health Organization. Globocan 2012 Stomach Cancer:<br \/>\n      Estimated Incidence, Mortality and Prevalence Worldwide in 2012. <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fglobocan.iarc.fr%2Fold%2FFactSheets%2Fcancers%2Fstomach-new.asp&amp;esheet=50951007&amp;newsitemid=20140928005065&amp;lan=en-US&amp;anchor=http%3A%2F%2Fglobocan.iarc.fr%2Fold%2FFactSheets%2Fcancers%2Fstomach-new.asp&amp;index=10&amp;md5=d08ce982a3bfec51cece69abac9495bd\" rel=\"nofollow\">http:\/\/globocan.iarc.fr\/old\/FactSheets\/cancers\/stomach-new.asp<\/a>.<br \/>\n      Accessed September 17, 2014.\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140928005065r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, 973-901-5722<br \/>or<br \/>Claire        Mulhearn, 908-423-7425<br \/>or<br \/>Investor:<br \/>Joseph Romanelli,        908-423-5185<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA \u00ae (pembrolizumab) \u2013 the company\u2019s anti-PD-1 therapy \u2013 in PD-L1 positive, advanced gastric cancer. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 31 percent with KEYTRUDA as monotherapy, as measured by investigator assessed, RECIST v1.1 (n= 12\/39: 95% CI, 17-47). Similar overall response rates were observed in Asian patients (a population with a high incidence of gastric cancer) and non-Asian patients. At the time of analysis, response durations ranged from 8+ to 20+ weeks with 11 of 12 responders continuing on therapy. These data, from a cohort of the ongoing Phase 1b KEYNOTE-012 study, were presented today, as part of a late-breaking oral session, by Dr. Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan, at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289,56],"class_list":["post-744922","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA \u00ae (pembrolizumab) \u2013 the company\u2019s anti-PD-1 therapy \u2013 in PD-L1 positive, advanced gastric cancer. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 31 percent with KEYTRUDA as monotherapy, as measured by investigator assessed, RECIST v1.1 (n= 12\/39: 95% CI, 17-47). Similar overall response rates were observed in Asian patients (a population with a high incidence of gastric cancer) and non-Asian patients. At the time of analysis, response durations ranged from 8+ to 20+ weeks with 11 of 12 responders continuing on therapy. These data, from a cohort of the ongoing Phase 1b KEYNOTE-012 study, were presented today, as part of a late-breaking oral session, by Dr. Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan, at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\\\/\",\"name\":\"Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-09-28T02:15:00+00:00\",\"dateModified\":\"2023-03-22T04:04:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA \u00ae (pembrolizumab) \u2013 the company\u2019s anti-PD-1 therapy \u2013 in PD-L1 positive, advanced gastric cancer. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 31 percent with KEYTRUDA as monotherapy, as measured by investigator assessed, RECIST v1.1 (n= 12\/39: 95% CI, 17-47). Similar overall response rates were observed in Asian patients (a population with a high incidence of gastric cancer) and non-Asian patients. At the time of analysis, response durations ranged from 8+ to 20+ weeks with 11 of 12 responders continuing on therapy. These data, from a cohort of the ongoing Phase 1b KEYNOTE-012 study, were presented today, as part of a late-breaking oral session, by Dr. Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan, at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:51+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/","name":"Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-09-28T02:15:00+00:00","dateModified":"2023-03-22T04:04:51+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-first-presentation-of-data-on-the-investigational-use-of-keytruda-pembrolizumab-in-patients-with-advanced-gastric-cancer-at-esmo-2014\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"02636233-0a33-41eb-b625-812769826176","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-First-Presentation-of-Data-on-the-Investigational-Use-of-KEYTRUDA-pembrolizumab-in-Patients-with-Advanced-Gastric-Can-G8G1K.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744922\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744922"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}